Bassi K K, Giri A K, Pattanayak M, Abraham S W, Pandey K K
Department of Surgical Oncology, Rockland Hospital, Qutab Institutional Area, New Delhi, India.
Indian J Cancer. 2012 Jan-Mar;49(1):114-8. doi: 10.4103/0019-509X.98934.
A totally implantable venous access port (TIVAP) has become an essential prerequisite for many chemotherapy protocols. It is serving its purpose very well, but its use is not without complications. We are presenting our experience with these devices (TIVAPs).
We retrospectively reviewed the totally implantable venous access ports in 81 patients at our hospital between January 2009 and March 2011 for long-term problems which include postoperative and follow-up problems, excluding the immediate complications which occur at the time of insertion.
Catheter malfunction was the most common complication (9.87%, 0.40/1000 device-days of use/observation). Catheter-related bloodstream infections were present in 5 (6.17%) patients (0.25/1000 device-days of use/observation). The mean life of the catheter was 246 days. Only 11.1% ports required removal during the treatment period. Overall, patients either completed treatment (82.8%) or died (6.1%) while receiving treatment.
TIVAPs provide safe and reliable vascular access for patients on chemotherapy but require utmost care by a dedicated team of trained medical professionals and paramedics experienced with the use of such ports, in order to minimize the complications and their continued use while administering treatment.
全植入式静脉输液港(TIVAP)已成为许多化疗方案的重要前提条件。它很好地发挥了作用,但使用过程并非没有并发症。我们在此介绍我们使用这些装置(TIVAP)的经验。
我们回顾性分析了2009年1月至2011年3月期间我院81例患者使用的全植入式静脉输液港,以了解包括术后及随访问题在内的长期问题,不包括置入时发生的即刻并发症。
导管故障是最常见的并发症(9.87%,每1000个装置使用/观察日0.40例)。5例(6.17%)患者发生导管相关血流感染(每1000个装置使用/观察日0.25例)。导管的平均使用期限为246天。治疗期间仅11.1%的输液港需要取出。总体而言,患者在接受治疗期间要么完成了治疗(82.8%),要么死亡(6.1%)。
TIVAP为化疗患者提供了安全可靠的血管通路,但需要由经验丰富的专业医疗团队和护理人员悉心护理,以尽量减少并发症并确保在治疗期间持续使用。